You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 4,145,433


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 4,145,433
Title: Method of treating helminthiasis by parenteral administration of sulfoxide derivatives of benzimidazoles
Abstract:A method is provided for treating or inhibiting helminthiasis by parenterally or topically administering sulfoxide derivatives of benzimidazoles having the structure ##STR1## wherein R.sup.1 is lower alkyl or phenyl-lower alkyl, R.sup.2 and R.sup.3 may be the same or different and are hydrogen or lower alkyl, R.sup.4 and R.sup.5 may be the same or different and are hydrogen, lower alkyl, lower alkoxy, halogen or nitro, and m is 0 to 3, n is 0 to 3, m + n being .ltoreq. 5. Pharmaceutical compositions for use in the above method are also provided.
Inventor(s): Haugwitz; Rudiger D. (Titusville, NJ), Cruthers; Larry R. (Flemington, NJ)
Assignee: E. R. Squibb & Sons, Inc. (Princeton, NJ)
Application Number:05/870,410
Patent Claims:1. A method of treating helminthiasis, which comprises parenterally administering to a mammalian host an effective amount of a compound of the structure ##STR4## wherein R.sup.1 is lower alkyl, phenyl-lower alkyl, R.sup.2 and R.sup.3 are the same or different and are selected from the group consisting of hydrogen and lower alkyl, and R.sup.4 and R.sup.5 may be the same or different and are selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, halogen and nitro, m is 0 to 3, n is 0 to 3 and m + n is .ltoreq. 5, dispersed in a non-toxic non-pyrogenic physiologically acceptable carrier.

2. The method as defined in claim 1 where in said compound R.sup.1 is lower alkyl or benzyl.

3. The method as defined in claim 1 where in said compound R.sup.2 and R.sup.3 are hydrogen or methyl.

4. The method as defined in claim 1 where in said compound R.sup.4 and R.sup.5 are hydrogen.

5. The method as defined in claim 1 where in said compound m is 0 and n is 0, and R.sup.2 and R.sup.3 are hydrogen.

6. The method as defined in claim 1 wherein said compound has the name [5-[(benzylsulfinyl]-1H-benzimidazol-2-yl]carbamic acid, methyl ester.

7. The method as defined in claim 1 wherein said compound has the name [5-[(phenethyl)sulfinyl]-1H-benzimidazol-2-yl]carbamic acid, methyl ester.

8. The method as defined in claim 1 wherein said compound is administered subcutaneously.

9. The method as defined in claim 1 wherein said compound is administered intravenously.

10. An injectable composition for use in treating helminthiasis in mammalian species comprising an effective amount of a compound of the structure ##STR5## wherein R.sup.1 is lower alkyl, phenyl-lower alkyl, R.sup.2 and R.sup.3 are the same or different and are selected from the group consisting of hydrogen and lower alkyl, and R.sup.4 and R.sup.5 may be the same or different and are selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, halogen and nitro, m is 0 to 3, n is 0 to 3 and m + n is .ltoreq. 5, and a non-toxic non-pyrogenic physiologically acceptable carrier therefor selected from the group consisting of benzyl benzoate, 1,3-butylene glycol, ethyl oleate, glyceryl triacetate, mixtures thereof, a mixture of benzyl benzoate and sesame oil, and sterile water for injection.

11. The composition as defined in claim 10 wherein said compound has the name [5-[(benzyl)sulfinyl]-1H-benzimidazol-2-yl]carbamic acid, methyl ester.

12. A method of treating helminthiasis, which comprises cutaneously administering to a mammalian host a compound of the structure ##STR6## wherein R.sup.1 is lower alkyl, phenyl-lower alkyl, R.sup.2 and R.sup.3 are the same or different and are selected from the group consisting of hydrogen and lower alkyl, and R.sup.4 and R.sup.5 may be the same or different and are selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, halogen and nitro, m is 0 to 3, n is 0 to 3 and m + n .ltoreq. 5, dispersed in a non-toxic non-pyrogenic physiologically acceptable carrier.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.